High prevalence of p53 exon 4 mutations in soft tissue sarcoma

Cancer

Volumn 109, Issue 11, 2007, Pages 2323-2333

  Das, Parimal ^a   Kotilingam, Dhanasekaran ^a   Korchin, Borys ^a   Liu, Jeuhui ^a   Yu, Dihua ^a   Lazar, Alexander J ^a   Pollock, Raphael E ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Exon 4; Immunohistochemistry; Mutations; p53; Sequencing; Soft tissue sarcoma

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE INSERTION; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INCIDENCE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; SARCOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34249010878     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22680     Document Type: Article

References (42)

1. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679-1689.
2. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719-2725.
3. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602-610; discussion 610-612.
4. Billingsley KG, Lewis JJ, Leung DH, Casper ES, Woodruff JM, Brennan MF. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999;85:389-395.
5. Latres E, Drobnjak M, Pollack D, et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol. 1994;145:345-355.
6. Taubert H, Meye A, Wurl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 1996;56:4134-4136.
7. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer. 1994;73:2499-2505.
8. Schneider-Stock R, Onnasch D, Haeckel C, Mellin W, Franke DS, Roessner A. Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch. 1999;435:407-412.
9. Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene. 1996;12:2035-2039.
10. Milas M, Yu D, Lang A, et al. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000;7:422-429.
11. Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res. 1998;4:1985-1994.
12. Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000;60:3655-3661.
13. Liu J, Zhan M, Hannay JA, et al. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res. 2006;4:803-810.
14. Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer. 2001; 92:1556-1566.
15. Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem. 2005;280:4825-4833. Erratum in: J Biol Chem. 2005;280: 22555.
16. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
17. Martin AC, Facchiano AM, Cuff AL, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002;19:149-164.
18. Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell. 2006;10:191-202.
19. Peart MJ, Prives C. Mutant p53 gain of function: the NF-Y connection. Cancer Cell. 2006;10:173-174.
20. Sigal A, Rotter V Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 2000;60:6788-6793.
21. Beroud C, Soussi T. p53 gene mutation: Software and database. Nucleic Acids Res. 1998;26:200-204.
22. Cariello NF, Beroud C, Soussi T. Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res. 1994;22:3549-3550.
23. Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998;26:205-213.
24. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. The UMD TP53 database and website: update and revisions. Hum Mutat. 2006;27:14-20.
25. Stockton DW, Das P, Goldenberg M, D'Souza RN, Patel PI. Mutation of PAX9 is associated with oligodontia. Nat Genet. 2000;24:18-19.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18: 695-706.
27. Andreassen A, Oyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 1993;53:468-471.
28. Castresana JS, Rubio MP, Gomez L, Kreicbergs A, Zetterberg A, Barrios C. Detection of TP53 gene mutations in human sarcomas. Eur J Cancer. 1995;31A:735-738.
29. Schneider-Stock R, Haeckel C, Radig K, Pein CD, Roessner A. Improved detection of p53 mutations in soft tissue tumors using new gel composition for automated nonradioactive analysis of single-strand conformation polymorphism. Electrophoresis. 1997;18:2849-2851.
30. Prescott JL, Montie J, Pugh TW, McHugh T, Veltri RW. Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer. 2001;91:2127-2135.
31. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996;13:1971-1981.
32. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch Pathol Lab Med. 1997;121:395-399.
33. Kitayner M, Rozenberg H, Kessler N, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006;22: 741-753.
34. Okorokov AL, Sherman MB, Plisson C, et al. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J. 2006;25:5191-5200.
35. Wang P, Reed M, Wang Y, et al. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol. 1994;14: 5182-5191.
36. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA. 1996;93:15335-15340.
37. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
38. Kinoshita Y, Shiratsuchi H, Tamiya S, et al. Mutations of the p53 gene in malignant rhabdoid tumors of soft tissue and the kidney: immunohistochemical and DNA direct sequencing analysis. J Cancer Res Clin Oncol. 2001;127: 351-358.
39. Schneider-Stock R, Radig K, Oda Y, et al. p53 gene mutations in soft-tissue sarcomas - correlations with p53 immunohistochemistry and DNA ploidy. J Cancer Res Clin Oncol. 1997;123:211-218.
40. Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol. 1996;9:1-6.
41. Stephen CW, Helminen P, Lane DP. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J Mol Biol. 1995;248:58-78.
42. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329-330.